'Unusual' Potential Migraine Comorbidities Doctors Are Still Trying to Explain

Everyone knows the usual suspects. Anxiety, depression, sleep disorders — when a migraine patient walks through the door, a neurologist mentally checks these boxes almost automatically. A 2024 meta-analysis in the European Journal of Neurology confirmed that pre-existing comorbidities are not just fellow travelers with migraine but may actually help predispose people to developing it in the first place. The relationship runs in both directions: having certain comorbidities raises migraine risk, and having migraine raises the risk of developing other conditions.

But medicine’s map of migraine keeps expanding. Beyond the standard list, “strange” (or less well understood) connections keep appearing in the data: a skin condition affecting the face, an autonomic nervous system disorder, a gynecological disease. The overlaps are real and measurable. The mechanisms are, in many cases, still anyone’s guess.

What follows is a tour through some of the most unexpected — and scientifically fascinating — conditions that keep turning up alongside migraine. Some are well-documented comorbidities. Others are at the “we’ve noticed something and need to talk about it” stage of research. All of them suggest that migraine is far more than a headache.

1. Rosacea

People with migraine get rosacea at higher rates than people without it — and the drug class used to prevent migraine attacks also seems to clear up rosacea’s hallmark flushing.

That drug class is CGRP inhibitors (calcitonin gene-related peptide inhibitors), and CGRP turns out to be the plot twist connecting these two apparently unrelated conditions. Rosacea, a chronic inflammatory skin disorder characterized by facial redness and flushing, was, until recently, considered a purely dermatological problem. Then researchers started looking at the underlying biology.

A 2024 cross-sectional study published in the Journal of the European Academy of Dermatology and Venereology found that plasma CGRP levels were significantly elevated in individuals with rosacea compared with controls, independent of whether they also had migraine. CGRP is the very same neuropeptide that triggers neurogenic inflammation in migraine. The fact that it is elevated in rosacea skin, even in people without migraine, suggests a shared inflammatory pathway.

The clinical implications are already being tested. A 2024 trial published in JAMA Dermatology found that erenumab (a CGRP receptor monoclonal antibody developed for migraine) significantly reduced persistent erythema and flushing in patients with treatment-resistant rosacea.

A separate 2024 cohort study from the University of Texas Medical Branch confirmed that migraine patients treated with CGRP inhibitor monoclonal antibodies developed rosacea at significantly lower rates than those treated with triptans or topiramate.

Researchers believe both conditions share triggers — emotional stress, UV exposure, heat, certain foods, and alcohol — and now appear to share a biological accelerant in CGRP-mediated neurogenic inflammation. In practical terms, this suggests neurologists treating migraine and dermatologists treating rosacea may increasingly find they are working on overlapping problems with overlapping tools.

2. Postural Orthostatic Tachycardia Syndrome (POTS)

POTS is a disorder of the autonomic nervous system in which standing up causes an abnormally high heart rate. It causes dizziness, fainting, chronic fatigue, brain fog, and — frequently — migraine.

A 2020 study in the journal Cephalalgia confirmed that up to 90% of POTS patients report headaches, and comorbid migraine headaches are common, hypothesizing that both conditions display features of central sensitization — the nervous system’s tendency to amplify pain signals — including allodynia and light sensitivity.

A 2022 narrative review in Headache: The Journal of Head and Face Pain went further, arguing there is genuine mechanistic overlap between the two conditions rather than coincidental coexistence. Both involve dysregulation of the autonomic nervous system, abnormal cerebrovascular regulation, and potentially shared inflammatory pathways. The high prevalence of migraine in POTS patients, the authors suggested, may not be random comorbidity — it may reflect common affected pathways.

Practically speaking, this is still under-recognized. Patients with migraine who also experience chronic dizziness, heart palpitations, fatigue, and orthostatic intolerance (feeling faint on standing) are increasingly being screened for POTS at specialist headache centers. Neurologists at the American Headache Society’s 2024 meeting emphasized that autonomic disorders, including POTS and orthostatic hypotension, are commonly found alongside hypermobility disorders and mast cell activation syndrome in patients with migraine who have multiple systemic symptoms.

In other words, if your migraines come packaged with fainting, fatigue, and a racing heart on standing — those symptoms may be part of a broader picture, not separate misfortunes.

3. Hypermobile Ehlers-Danlos Syndrome (hEDS)

Hypermobile Ehlers-Danlos Syndrome — a heritable connective tissue disorder characterized by extremely flexible joints, stretchy skin, and chronic pain — sounds at first like it has nothing to do with headaches. But in clinical practice, the connection is startling.

A 2024 review in Frontiers in Neurology reported that migraine is found in up to three-quarters of patients with symptomatic joint hypermobility — and that those patients tend to have higher headache frequency and an earlier age of onset than the general population. A 2023 study in Genetics in Medicine Open confirmed that people with hEDS have a significantly higher risk of experiencing migraine headaches, POTS, and fibromyalgia compared to the general population.

The proposed mechanisms are multiple. Ligament weakness and joint instability can cause cervical (neck) instability and pressure on upper cervical nerves, creating a mechanical trigger for head pain. Connective tissue abnormalities may affect blood vessel walls, which matters because migraine involves abnormal dilation of cranial blood vessels. There may also be shared mast cell biology—hEDS is associated with mast cell activation, and mast cells contribute to neurogenic inflammation.

People with hEDS often spend years — even decades — in a diagnostic odyssey. They are told their symptoms are anxiety, hypochondria, or “just stress.” Understanding that migraine frequently coexists with hEDS, and that both may be manifestations of underlying connective tissue dysfunction, can speed diagnosis and improve treatment. A multidisciplinary team — neurologist, rheumatologist, physiotherapist — is typically needed.

4. Mast Cell Activation Syndrome (MCAS)

Mast cells are immune cells that live in tissues throughout the body and release inflammatory chemicals — histamine, prostaglandins, cytokines — in response to threats. In MCAS, they release these chemicals inappropriately and excessively, causing a bewildering range of symptoms: flushing, hives, gastrointestinal distress, brain fog, and anaphylaxis-like reactions.

And migraines. Lots of migraines.

A 2023 review in Current Neurology and Neuroscience Reports specifically examined the overlap between migraine, dysautonomia, hypermobility spectrum disorders, and MCAS, finding that “numerous studies indicate a significant overlap and shared pathophysiology.” Migraine is described as one of the most common comorbidities of MCAS.

A 2024 review in the World Journal of Gastroenterology noted that research has linked the parasympathetic nervous system, mast cells, and migraine, with evidence suggesting that endogenous acetylcholine can activate meningeal mast cells, contributing directly to migraine pathophysiology. The meninges — the membranes surrounding the brain — are rich in mast cells, and their activation contributes to the neurogenic inflammation that is central to migraine attacks.

For patients, this overlap is particularly frustrating to navigate because MCAS itself remains underrecognized and difficult to diagnose. Many patients with complex migraines plus flushing, food sensitivities, gastrointestinal issues, and allergy-like reactions may benefit from MCAS investigation. Treatment with antihistamines and mast cell stabilizers has helped some migraine patients whose condition was not responding to conventional preventives.

5. Endometriosis 

Endometriosis, the condition in which uterine-like tissue grows outside the uterus, causing severe pelvic pain and sometimes infertility, among many other painful symptoms, is another disease where migraine keeps showing up uninvited.

A 2025 systematic review and meta-analysis published in The Journal of Headache and Pain confirmed that migraine is significantly more common in women with endometriosis than in the general population. One observational cross-sectional study it reviewed found a comorbid migraine prevalence of 54% in women with endometriosis — more than twice the rate in the general female population.

A 2024 case-control study in Cephalalgia found that women with both conditions had more severe symptoms overall — higher pain scores for both conditions and a significantly higher rate of migraine with aura. Importantly, the study found that severe forms of endometriosis (posterior and anterior deep infiltrating endometriosis) occurred more frequently in women who also had migraine.

Both endometriosis and migraine are strongly influenced by hormonal fluctuations, particularly estrogen. Menstrual migraine is a well-established phenomenon — the estrogen drop before menstruation reliably triggers attacks in many. Endometriosis is driven by estrogen, and the inflammatory environment it creates may lower the threshold for pain sensitization more broadly, including in the trigeminal system that drives migraine.

A 2025 study in npj Women’s Health, using a large U.K. electronic healthcare dataset, confirmed a higher prevalence of migraine among endometriosis patients using data-driven methods — strengthening the case that this is a genuine, reproducible association rather than due to ascertainment bias.

6. Tinnitus

The ear and the migraine brain turn out to have more in common than either would like to admit.

A 2021 cross-sectional analysis of the National Health and Nutrition Examination Survey (NHANES) — covering more than 12,000 Americans — found that migraine patients were significantly more likely to have tinnitus (34.6% vs. 19.9% in non-migraineurs) and subjective hearing loss (25% vs. 16.6%). Of all people in the database with tinnitus, 35.6% also reported migraine. The associations held after controlling for age, sex, BMI, and noise exposure.

A 2024 case-control study enrolled 298 patients with primary tinnitus and found that those with comorbid migraine or vestibular migraine had significantly better pure-tone hearing thresholds, but that migraine was a powerful predictor of tinnitus severity overall,

7. A Disruption in the Gut Microbiome

If the previous entries seemed surprising, this one tends to produce genuine skepticism, which the science is gradually wearing down.

A 2025 systematic review in The Journal of Headache and Pain synthesized evidence from multiple human cohort studies and concluded that migraine patients show distinct alterations in gut microbiome composition compared to healthy controls. The review identified specific bacterial genera — including Faecalibacterium, Bifidobacterium, Lactobacillus, and Clostridium — as differing between migraineurs and non-migraineurs in ways that are beginning to look consistent across populations.

A 2022 study in Frontiers in Neurology examined the gut microbiome in migraine patients with irritable bowel syndrome (IBS) — a common pairing — and found that this subgroup exhibited distinct dysbiosis compared with IBS patients without migraine, suggesting the two conditions may interact at the microbiome level.

The gut-brain axis — the bidirectional communication network between gut bacteria and the central nervous system — is the proposed mechanism. Gut microbiota influence serotonin production (the gut produces approximately 90% of the body’s serotonin), inflammatory cytokine levels, and the vagus nerve, all of which have established roles in migraine.

A 2024 randomization study in Frontiers in Microbiology — a research design that helps establish causality rather than just correlation — found evidence supporting a causal relationship between specific gut microbial taxa and migraine risk.

It is important to be clear about what remains unknown: We do not have evidence that probiotics alone can cure or prevent migraine. But the microbiome-migraine connection is moving from curiosity to a legitimate research frontier, with clinical trials of dietary and microbiome-targeted interventions now underway.

8. Fibromyalgia

Fibromyalgia — widespread musculoskeletal pain, fatigue, cognitive dysfunction, and sleep disturbance — is listed in textbooks as a migraine comorbidity, but the extent of the overlap is often underappreciated.

The shared mechanism appears to be central sensitization: a state in which the central nervous system is wound up, processing pain signals at amplified volume. In both migraine and fibromyalgia, pain thresholds are lowered, the nervous system overreacts to stimuli, and the boundary between warning signal and full-blown attack becomes dangerously thin.

A 2024 clinical study from Istanbul University examining fibromyalgia in chronic migraine patients found that the presence of fibromyalgia significantly worsened outcomes — higher disability scores, more frequent attacks, poorer quality of life — underlining that these conditions do not merely coexist passively; they amplify each other.

Clinicians increasingly recognize that patients with refractory chronic migraine (migraine that does not respond well to standard treatments) are more likely to have undiagnosed fibromyalgia. Treating the fibromyalgia — through aerobic exercise, certain antidepressants, and central sensitization-focused approaches — can sometimes improve migraine control where headache-specific treatments have failed.

What All of These Have in Common

Look across these eight conditions, and patterns emerge.

• CGRP and neurogenic inflammation. The same molecule driving migraine attacks — CGRP — appears in elevated levels in rosacea, drives symptoms in POTS via vasodilation, and is implicated in mast cell degranulation. The new class of migraine drugs targeting CGRP may turn out to have applications well beyond headache.
• Central sensitization. The nervous system that amplifies migraine pain is the same system implicated in fibromyalgia, MCAS-related hypersensitivity, and the lowered pain thresholds seen in hEDS. A chronically sensitized nervous system may be the unifying biology underneath many of these overlaps.
• Estrogen and sex hormones. The strong female predominance across migraine, endometriosis, POTS, hEDS, and MCAS is not coincidental. Estrogen influences mast cell function, autonomic regulation, pain thresholds, and vascular tone — making it a biological thread running through several of these comorbidities simultaneously.
• The gut-brain-immune axis. Microbiome alterations, mast cell dysregulation, and IBS overlap with migraine in ways that point toward systemic inflammation and neuroimmune dysfunction as a broader underlying state, not just a collection of bad luck.
• The diagnostic mystery problem. Many of the conditions in this list — POTS, hEDS, MCAS, endometriosis — share the dubious distinction of taking years to diagnose. Patients are frequently told their symptoms are psychological, and they rotate through specialists who see only their slice of the problem. Migraines sit at the center of this web for many patients. A clinician who understands these connections might be the one who finally asks the right question that unlocks the broader diagnosis.

A Note on Where the Research Stands

Some of the associations above — rosacea, tinnitus, endometriosis, MCAS — are supported by strong epidemiological data, but the mechanistic understanding remains incomplete. Others — like the gut microbiome connection — are moving toward causal evidence but have not yet translated into clinical protocols. That uncertainty is normal in medicine: the association between smoking and lung cancer was observed decades before the molecular mechanisms were understood.

What these findings collectively suggest is that migraine is not a skull-contained event. It reflects a state of the whole nervous system, and often of the whole body. Treating it well may ultimately require recognizing the larger ecosystem in which it lives.

The era of the “headache specialist” may be giving way to something broader: a systems-level understanding of the migraine patient as someone whose brain, immune system, gut, connective tissue, and hormonal environment are all participating in the same story. That is more complex than a headache. But it is also, arguably, more hopeful — because it multiplies the entry points for effective treatment.

If you have migraine alongside any of the conditions described here, that combination is worth discussing explicitly with your care team. The clusters are not random. And the treatment implications are real.